2020
Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
Abu Raya M, Klein A, Sabo E, Yaccob A, Baruch Y, Khoury J, Saadi T. Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease. Israel Medical Association Journal 2020, 22: 320-325. PMID: 32378826.Peer-Reviewed Original ResearchConceptsHepatitis C virusViral responseInflammatory cellsChronic hepatitis C virusChronic HCV infectionChronic liver diseaseEra of treatmentLiver needle biopsyNon-SVRHCV infectionCollagen fibersLiver unitPeg-interferonLiver diseaseHistological findingsC virusHistomorphometric findingsLeading causeNeedle biopsyHistological variablesPatient responseLiver architectureTreatment responseHepatocellular carcinomaPrevious patients
2019
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. Journal Of Gastrointestinal Cancer 2019, 51: 584-590. PMID: 31407252, DOI: 10.1007/s12029-019-00293-y.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCohort StudiesFemaleHepatitis C, ChronicHumansMaleMiddle AgedNeoplasmsRetrospective StudiesConceptsHepatitis C virusExtrahepatic malignanciesAntiviral agentsParitaprevir/ritonavir/ombitasvirChronic hepatitis C virusRecurrent metastatic breast cancerRecurrent transitional cell carcinomaMethodsFour hundred thirtyChronic HCV infectionDirect antiviral agentsMetastatic breast cancerTreatment of choiceTransitional cell carcinomaPossible relationshipDAA treatmentResultsNine patientsHCV infectionCommon regimenCell carcinomaC virusLaryngeal carcinomaPancreatic adenocarcinomaLung carcinomaBreast cancerUrinary bladder
2018
Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? Journal Of Clinical Gastroenterology 2018, 52: 353-359. PMID: 28590324, DOI: 10.1097/mcg.0000000000000853.Peer-Reviewed Original ResearchConceptsDirect antiviral agentsAdverse eventsHepatocellular carcinomaAntiviral agentsChronic hepatitis C virus (HCV) infectionParitaprevir/ritonavir/ombitasvirHepatitis C virus infectionDe novo hepatocellular carcinomaLarge clinical trial dataSerum HCV RNAC virus infectionNovo hepatocellular carcinomaTreatment of choiceTransitional cell carcinomaAggressive hepatocellular carcinomaAggressive transitional cell carcinomaClinical trial dataDevelopment of malignancyHCV infectionHCV RNAHCV genotypesLiver diseaseCell carcinomaLaryngeal carcinomaPancreatic adenocarcinoma
2017
Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study
Khoury J, Szwarcwort M, Kra-oz Z, Saffuri M, Seh K, Yahalomi T, Braun E, Azzam Z, Paul M, Neuberger A. Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study. European Journal Of Clinical Microbiology & Infectious Diseases 2017, 37: 319-323. PMID: 29143145, DOI: 10.1007/s10096-017-3135-0.Peer-Reviewed Original ResearchConceptsRisk factorsBlood pressureDiagnostic yieldDay 2Lower diastolic blood pressureNegative PCR testIndependent risk factorProspective cohort studyProspective observational studyDiastolic blood pressureLower blood pressurePCR testInitiation of treatmentLow diagnostic yieldFirst positive testEvaluable patientsInfluenza PCROseltamivir administrationOseltamivir treatmentCohort studyMedian ageAdult inpatientsViral sheddingPositive PCRPCR positivity
2016
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection
Saadi T, Khoury J. Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection. Journal Of Clinical Gastroenterology 2016, 50: 799. PMID: 27380458, DOI: 10.1097/mcg.0000000000000587.Commentaries, Editorials and LettersMeSH Keywords2-NaphthylamineAlanine TransaminaseAnilidesAntiviral AgentsAspartate AminotransferasesCarbamatesCyclopropanesDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsMiddle AgedProlineRibavirinRitonavirSulfonamidesUracilValineWithholding Treatment